Thursday, July 9, 2026

pharma · Familial adenomatous polyposis (FAP) · Familial Adenomatous Polyposis · BDRX

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals is a pharma organization headquartered in cardiff, GB. It trades on NYSE under ticker BDRX. Primary therapeutic focus areas include Familial adenomatous polyposis (FAP), Familial Adenomatous Polyp

cardiff, GB HQ
2000 Founded
25 Employees
Public company Type
BDRX · NYSE Ticker
Company details
Status
Public
HQ
cardiff, GB
Founded
2000
Employees
25
Programs
4
Drugs
5
Patents
2
Clinical program

Encapsulated Rapamycin (eRapa)

Phase 2 · small molecule · Familial Adenomatous Polyposis

Encapsulated Rapamycin (eRapa) for Familial Adenomatous Polyposis is a Phase 2 program (small_molecule) at Biodexa Pharmaceuticals Plc with 1 ClinicalTrials.gov record(s).

Internal code EMT-FAP-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Biodexa Pharmaceuticals Plc
Phase
Phase 2
Modality
small_molecule
Indication
Familial Adenomatous Polyposis
Status
active
Trials
1